Rituximab treatment of refractory rheumatoid arthritis

Annals of Pharmacotherapy

Volumn 39, Issue 12, 2005, Pages 2091-2095

  Summers, Kelly M ^a,b   Kockler, Denise R ^a,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Rheumatoid arthritis; Rituximab

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; CD20 ANTIBODY; CHIMERIC MONOCLONAL ANTIBODY CD20; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALGORITHM; B LYMPHOCYTE; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EMBASE; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOPATHOGENESIS; LONG TERM CARE; LYMPHOCYTE COUNT; MEDLINE; OPEN STUDY; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CLINICAL TRIALS; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 28544445794     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G311     Document Type: Review

References (23)

1. Lawrence RC, Helmick CG, Arnett FC, Dayo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Symmons DP, Barrett EM, Bankhead CR, Scott DG, Silman AJ. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthrius Register. Br J Rheumatol 1994;33:735-9.
3. Panayi GS. The immunopathogenesis of rheumatoid arthritis. Br J Rheumatol 1993;32(suppl 1):4-14.
4. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001;44:1234-6.
5. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthrius. N Engl J Med 2001;344:907-16.
6. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
7. Mariette X. The B cell: a new therapeutic target in rheumatoid arthritis and other autoimmune diseases. Joint Bone Spine 2005;71:357-60.
8. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 2003;5(suppl 4):S1-6.
9. Zhang Z, Bridges SL Jr. Pathogenesis of rheumatoid arthritis: role of B lymphocytes. Rheum Dis Clin North Am 2001;27:335-53.
10. Cause A, Berek C. The role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. BioDrugs 2001;15:73-9.
11. Keystone EC. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology 2005;44(suppl 2):ii8-12.
12. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology 2004;44(suppl 2):ii3-7.
13. Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease. Arthritis Res Ther 2003;5(suppl 4):S17-21.
14. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92.
15. Package insert. Rituxan (rituximab). South San Francisco, CA: Genentech, January 2005.
16. Protheroe A, Edwards JCW, Simmons A, Maclennan K, Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy in non-Hodgkin's lymphoma. Rheumatology 1999;38:1150-2.
17. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40:205-11.
18. Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.
19. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum 2002;46:2029-33.
20. Moore J, Ma D, Will R, Cannell P, Handel M, Milliken S. A Phase II study of rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant 2004;34:241-7.
21. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
22. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
23. O'Dell J. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.